DRTS
Alpha Tau Medical
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
consensus rating "Strong Buy"
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About DRTS
Alpha Tau Medical Ltd.
A developer of alpha radiation cancer therapy designed to treat solid tumors
Life Science Tools and Services
Invalid Date
03/08/2021
NASDAQ Stock Exchange
125
12-31
Common stock
Kiryat HaMada St. 5, Jerusalem 9777605, Israel
--
Alpha Tau Medical Ltd., a company established in Israel in 2016. The Company is a clinical-stage oncology company focused on local radiotherapy for solid tumors utilizing innate relative bioavailability and short-course α granules. The company's proprietary Alpha DaRT technology is designed to take advantage of the specific therapeutic properties of alpha particles, while aiming to overcome or even exploit the traditional disadvantages of limited range of alpha radiation for potential benefits. The company has conducted several clinical trials in clinical sites around the world to evaluate and continue to evaluate the feasibility, safety and efficacy of Alpha DaRT technology in the treatment of superficial lesions, namely skin, head or neck tumors.
Company Financials
EPS
DRTS has released its 2024 Q4 earnings. EPS was reported at -0.14, versus the expected -0.13, missing expectations. The chart below visualizes how DRTS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
